Home > Resources > Whitepapers > Accelerating precision medicine

Accelerating precision medicine

October 17, 2017

The fully realized vision of precision medicine includes the capability to rapidly diagnose, sequence and develop a personalized treatment plan based on combined analysis of genotype, phenotype, environmental, clinical and behavioral data. Precision medicine can be advanced through the “All of Us” research initiative of the Precision Medicine Initiative, the most ambitious accumulation of human genomic, personal health and clinical information in history; but accelerating precision medicine to achieve this vision will require new capabilities and speed in personal health, clinical and genomic data storage transfer and analysis, as well as in interoperability and security. Further, precision medicine will demand new private sector, legislative and regulatory approaches for review and approval of genomic sequencing technologies and other software and devices needed to advance knowledge of disease factors that demonstrate variability among individuals.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

Foster Healthcare

Foster Healthcare is a C.H.A.P. Accredited Home Health provider with a focus on patient centered practices. INcompass - our industry first Transitional Care Program - leverages comprehensive care coordination with the latest Wireless Tele-Health technology to keep stakeholders informed of changes in patient condition. Our Care Team approach includes Nurses, Therapists, Social Workers and Certified Home Health Aides to keep patients out of the Hospital and in their homes where they belong.

OTHER WHITEPAPERS
news image

NEXTGEN PHARMA TAKES ‘SMART’ STRIDES WITH INTERNET OF THINGS

whitePaper | December 20, 2022

Digitization of processes and data across the value chain along with the emergence of Internet of Things (IoT) has transformed the Pharma industry.

Read More
news image

Essential for Stable U.S. Supply Chains of Quality Pharmaceuticals

whitePaper | May 11, 2022

CDER is taking another step towards realizing the vision for pharmaceutical quality in the 21st century: a maximally efficient, agile, flexible manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.

Read More
news image

Multi-channel clinical trial recruitment technology checklist

whitePaper | August 8, 2022

Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.

Read More
news image

The Next Generation of Rare Disease Drug Policy

whitePaper | April 7, 2022

The United States defines a rare disease as a condition affecting fewer than 200,000 people in the country or one in which “there is no reasonable expectation” of recovering research and development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis, and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy

Read More
news image

Pharma R&D Annual Review

whitePaper | March 15, 2022

Successes in 2021 – New active substance drug launches

Read More
news image

The Age of Coaching

whitePaper | March 4, 2022

The pandemic has been healthcare and the pharmaceutical industry’s meteor moment established eco-systems have been wiped out andsales force routines have been scorched from the face of the earth.

Read More

NEXTGEN PHARMA TAKES ‘SMART’ STRIDES WITH INTERNET OF THINGS

whitePaper | December 20, 2022

Digitization of processes and data across the value chain along with the emergence of Internet of Things (IoT) has transformed the Pharma industry.

Read More

Essential for Stable U.S. Supply Chains of Quality Pharmaceuticals

whitePaper | May 11, 2022

CDER is taking another step towards realizing the vision for pharmaceutical quality in the 21st century: a maximally efficient, agile, flexible manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.

Read More

Multi-channel clinical trial recruitment technology checklist

whitePaper | August 8, 2022

Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.

Read More

The Next Generation of Rare Disease Drug Policy

whitePaper | April 7, 2022

The United States defines a rare disease as a condition affecting fewer than 200,000 people in the country or one in which “there is no reasonable expectation” of recovering research and development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis, and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy

Read More

Pharma R&D Annual Review

whitePaper | March 15, 2022

Successes in 2021 – New active substance
drug launches

Read More

The Age of Coaching

whitePaper | March 4, 2022

The pandemic has been healthcare and the pharmaceutical industry’s meteor moment established eco-systems have been wiped out and sales force routines have been scorched from the face of the earth. 

Read More
More Whitepapers

Spotlight

Foster Healthcare

Foster Healthcare is a C.H.A.P. Accredited Home Health provider with a focus on patient centered practices. INcompass - our industry first Transitional Care Program - leverages comprehensive care coordination with the latest Wireless Tele-Health technology to keep stakeholders informed of changes in patient condition. Our Care Team approach includes Nurses, Therapists, Social Workers and Certified Home Health Aides to keep patients out of the Hospital and in their homes where they belong.

Events

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference